Perflutren Patent Expiration
Perflutren is used for medical imaging using ultrasound technology. It was first introduced by Lantheus Medical Imaging Inc
Perflutren Patents
Given below is the list of patents protecting Perflutren, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Definity | US10588988 | Methods and devices for preparation of ultrasound contrast agents | May 04, 2037 | Lantheus Medcl |
| Definity Rt | US10588988 | Methods and devices for preparation of ultrasound contrast agents | May 04, 2037 | Lantheus Medcl |
| Definity | US10583208 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity | US11266750 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity | US11529431 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity | US11857646 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity | US11925695 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity | US12161730 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity | US9789210 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity Rt | US10583208 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity Rt | US11266750 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity Rt | US11529431 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity Rt | US11857646 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity Rt | US11925695 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity Rt | US12161730 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity Rt | US9789210 | Methods for making ultrasound contrast agents | Mar 16, 2037 | Lantheus Medcl |
| Definity | US10583207 | Lipid-encapsulated gas microsphere compositions and related methods | Dec 28, 2035 | Lantheus Medcl |
| Definity Rt | US10022460 | Lipid-encapsulated gas microsphere compositions and related methods | Dec 28, 2035 | Lantheus Medcl |
| Definity Rt | US10583207 | Lipid-encapsulated gas microsphere compositions and related methods | Dec 28, 2035 | Lantheus Medcl |
| Definity Rt | US11395856 | Lipid-encapsulated gas microsphere compositions and related methods | Dec 28, 2035 | Lantheus Medcl |
| Definity | US8658205 | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Jun 18, 2019
(Expired) | Lantheus Medcl |
| Definity | US8685441 | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Jan 13, 2019
(Expired) | Lantheus Medcl |
| Definity | US9545457 | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Jan 13, 2019
(Expired) | Lantheus Medcl |
| Definity | US6033645 | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
Jun 19, 2016
(Expired) | Lantheus Medcl |
| Definity | US5527521 | Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications |
Feb 22, 2015
(Expired) | Lantheus Medcl |
| Definity | US5585112 | Method of preparing gas and gaseous precursor-filled microspheres |
Dec 17, 2013
(Expired) | Lantheus Medcl |
Perflutren's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Perflutren:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| SHAPE Neoadjuvant Chemotherapy Response | Kibo Nam | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer | Thomas Jefferson University | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT) | Children's National Research Institute | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | UNC Lineberger Comprehensive Cancer Center | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |